In mouse models of different types of cancer, scientists at The Ohio State University boosted activation of T cells inside tumors in a way that improved their interactions with an antibody therapy currently being tested in clinical trials. The researchers injected nanoparticles carrying messenger RNA, molecules that translate genetic information into proteins, directly into the tumor site to help T cells generate specific receptors on their surfaces. Experimental monoclonal antibodies delivered six hours later could then bind to those receptors to carry out their cancer cell-killing functions.
An official website of the United States government.